LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Corvus Pharmaceuticals Inc

Fechado

3.94 0.77

Visão Geral

Variação de preço das ações

24h

Atual

Mín

3.93

Máximo

3.98

Indicadores-chave

By Trading Economics

Rendimento

27M

15M

EPS

-0.138

Funcionários

31

EBITDA

-1.8M

-9.9M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+232.48% upside

Dividendos

By Dow Jones

Próximos Ganhos

5 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

34M

311M

Abertura anterior

3.17

Fecho anterior

3.94

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

Corvus Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

6 de jun. de 2025, 14:31 UTC

Ganhos

New York State Retirement Fund Posts 5.84% Annual Investment Return

6 de jun. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

6 de jun. de 2025, 20:50 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

6 de jun. de 2025, 20:33 UTC

Ganhos

These Stocks Moved the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 de jun. de 2025, 19:36 UTC

Conversa de Mercado

Oil Futures Post Solid Weekly Gains -- Market Talk

6 de jun. de 2025, 19:28 UTC

Conversa de Mercado

U.S. Natural Gas Futures Rise on Demand Expectations -- Market Talk

6 de jun. de 2025, 18:46 UTC

Conversa de Mercado

Gold Faced With Tariff Uncertainty Offset by ETF Withdrawals -- Market Talk

6 de jun. de 2025, 18:02 UTC

Conversa de Mercado

U.S. Oil Rig Count Continues to Decline -- Market Talk

6 de jun. de 2025, 16:35 UTC

Ganhos

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 de jun. de 2025, 16:34 UTC

Ganhos

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 de jun. de 2025, 16:21 UTC

Conversa de Mercado

Canadian Unemployment Set to Continue Feel Trade War Pressures -- Market Talk

6 de jun. de 2025, 16:20 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

6 de jun. de 2025, 16:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

6 de jun. de 2025, 16:20 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

6 de jun. de 2025, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

6 de jun. de 2025, 16:07 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

6 de jun. de 2025, 16:07 UTC

Conversa de Mercado

Base Metal Prices Slide But Copper Set to End Week Higher -- Market Talk

6 de jun. de 2025, 15:53 UTC

Conversa de Mercado

Mexican Inflation Seen Rising in May -- Market Talk

6 de jun. de 2025, 15:36 UTC

Conversa de Mercado

Dollar's Boost From U.S. Jobs Data Could Be Limited -- Market Talk

6 de jun. de 2025, 15:36 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

6 de jun. de 2025, 15:33 UTC

Conversa de Mercado

Gold Futures Slide After Jobs Data Surprises to Upside -- Market Talk

6 de jun. de 2025, 15:16 UTC

Conversa de Mercado

Tesla Showing Signs of Weakness in Key Regions -- Market Talk

6 de jun. de 2025, 15:05 UTC

Conversa de Mercado

Silver at its Highest In Nearly 15 Years -- Market Talk

6 de jun. de 2025, 14:35 UTC

Conversa de Mercado

Weakening Canadian Job Market Seen Keeping BoC in Easing Mode -- Market Talk

6 de jun. de 2025, 14:28 UTC

Conversa de Mercado

Bitcoin Rises After Above-Forecast U.S. Jobs Data -- Market Talk

6 de jun. de 2025, 14:28 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

6 de jun. de 2025, 14:28 UTC

Conversa de Mercado

Canada's Job Market Weakens But Not Seen Collapsing -- Market Talk

6 de jun. de 2025, 14:15 UTC

Conversa de Mercado

Oil Rises on U.S.-China Talks Optimism -- Market Talk

6 de jun. de 2025, 14:12 UTC

Ganhos

Palantir and Super Micro Computer Stocks Rise as Broadcom Posts Strong AI Revenue -- Barrons.com

6 de jun. de 2025, 14:09 UTC

Ganhos

Broadcom, the $1 Trillion Stock You Shouldn't Ignore, Makes AI Investment Case -- Barrons.com

Comparação entre Pares

Variação de preço

Corvus Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

232.48% parte superior

Previsão para 12 meses

Média 13 USD  232.48%

Máximo 17 USD

Mínimo 11 USD

Com base em 3 analistas de Wall Street que oferecem metas de preço de 12 meses para Corvus Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

3 ratings

3

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

3.165 / 3.5827Suporte e Resistência

Curto Prazo

Strong Bearish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Weak Bearish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.